<DOC>
	<DOCNO>NCT00001096</DOCNO>
	<brief_summary>To assess safety immune response two experimental vaccine formulate QS-21 QS-21 plus alum . To determine whether new preparation QS-21 polysorbate 80 less reactogenic QS-21 formulation use AVEG Protocols 016 , 016A , 016B . To examine whether QS-21 immunologically equivalent used 16B . To determine QS-21 , give low dos antigen , induces measurable HIV-1-specific CTL activity . To evaluate QS-21 dose-sparing effect extend antigen dose 0.5 microgram . To determine bivalent vaccine give response equivalent monovalent product broaden HIV-1-specific binding neutralize antibody response occurs . An effective vaccine prevent HIV-1 infection may need generate diverse multifaceted immunologic response . Required part immune response may include : humoral antibody , broadly neutralize non-syncytium-inducing strain HIV-1 ; T cell help provide CD4 CD8 positive subset ; class I-restricted cytotoxic lymphocyte response . Other effector response , generation antibody-dependent cellular cytotoxicity , cytokine , chemokines , antiviral factor may also critical mount protective immunity . Given lack surrogate immunologic marker , practical approach possible efficacy trial would evaluate candidate vaccine elicit many response possible .</brief_summary>
	<brief_title>A Phase I , Multicenter , Randomized , Double-Blind , Placebo-Controlled Trial Evaluate Safety Immunogenicity HIV-1 MN rsgp120 Bivalent AIDSVAX B/E ( HIV-1 MN rgp120/A244 rgp120 ) Combination With QS-21 With Without Alum Healthy HIV-1 Uninfected Adults</brief_title>
	<detailed_description>An effective vaccine prevent HIV-1 infection may need generate diverse multifaceted immunologic response . Required part immune response may include : humoral antibody , broadly neutralize non-syncytium-inducing strain HIV-1 ; T cell help provide CD4 CD8 positive subset ; class I-restricted cytotoxic lymphocyte response . Other effector response , generation antibody-dependent cellular cytotoxicity , cytokine , chemokines , antiviral factor may also critical mount protective immunity . Given lack surrogate immunologic marker , practical approach possible efficacy trial would evaluate candidate vaccine elicit many response possible . Volunteers 5 group receive vaccine placebo intramuscular injection Months 0 , 1 , 6 . All patient receive one two dose QS-21 along vaccine placebo group receive alum follow : Group 1 : low-dose MN rsgp120/HIV-1 plus QS-21 ( 13 volunteer ) . Group 2 : high-dose MN rsgp120/HIV-1 plus QS-21 ( 13 volunteer ) . Group 3 : AIDSVAX B/E ( injection contain two vaccine component , HIV-1 MN rgp120 A244 rgp120/HIV-1 ) plus QS-21 plus alum ( 13 volunteer ) . Group 4 : high-dose MN rgp120/HIV-1 plus QS-21 plus alum ( 13 volunteer ) . Group 5 : placebo plus QS-21 ( 8 volunteer ) . Volunteers closely monitor immunization follow minimum 12 month initial immunization .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Inclusion Criteria Volunteers must : Negative ELISA HIV within 8 week prior immunization . CD4 count great equal 400 cells/mm3 . Normal history physical examination . [ Refer Laboratory value additional requirement . ] Exclusion Criteria Coexisting Condition : Volunteers follow condition symptom exclude : Medical psychiatric condition occupational responsibility preclude subject compliance protocol . Recent suicidal ideation psychosis . Active syphilis . NOTE : If serology document false positive due remote ( great 6 month ) treat infection , volunteer eligible . Active tuberculosis . NOTE : Volunteers positive PPD normal chest xray show evidence TB require INH therapy eligible . Positive hepatitis B surface antigen . Volunteers follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease . History cancer unless surgical excision follow sufficient observation period give reasonable assurance cure . History suicide attempt , recent suicidal ideation , past present psychosis . History anaphylaxis serious adverse reaction vaccine . History serious allergic reaction substance require hospitalization emergency medical care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) . History reaction thimerosal . Prior Medication : Excluded : Live attenuated vaccine within 60 day study . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclusionary , give least 2 week away HIV immunization . Experimental agent within 30 day prior study . HIV1 vaccine placebo part previous HIV vaccine trial . Prior Treatment : Excluded : Blood product immunoglobulin past 6 month . Experimental agent within 30 day prior study . Risk Behavior : Excluded : Volunteers identifiable high intermediaterisk sexual behavior HIV infection ( i.e. , AVEG Risk Groups C D ) . History intravenous drug use within 12 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV Antibodies</keyword>
	<keyword>HIV Antigens</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>T-Lymphocytes , Cytotoxic</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>Alum Compounds</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>